The New England journal of medicine, 2009-09, Vol.361 (12), p.1164-1172
2009
Details
- Autor(en) / Beteiligte
- Titel
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- Ist Teil von
- The New England journal of medicine, 2009-09, Vol.361 (12), p.1164-1172
- Ort / Verlag
- Waltham, MA: Massachusetts Medical Society
- Erscheinungsjahr
- 2009
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The hedgehog pathway is active during embryonic development but dormant after birth. Mutations constitutively activate hedgehog genes in basal-cell carcinoma. This phase 1 trial tested the safety and antitumor activity of an inhibitor of the hedgehog pathway (GDC-0449) in patients with locally advanced or metastatic basal-cell carcinoma whose tumors were inoperable or had not responded to previous therapy. The drug appeared to have antitumor activity in patients with basal-cell carcinoma. This phase 1 trial tested the safety and antitumor activity of an inhibitor of the hedgehog pathway (GDC-0449) in patients with locally advanced or metastatic basal-cell carcinoma whose tumors were inoperable or had not responded to previous therapy. The drug appeared to have antitumor activity in patients with basal-cell carcinoma. Basal-cell carcinoma, the most common skin cancer in the United States, has an estimated annual incidence of 0.1 to 0.5%. 1 , 2 The disease is largely caused by exposure to ultraviolet radiation, but there are other risk factors. 3 , 4 Surgery cures most cases of basal-cell carcinoma, but in a few patients there is progression to life-threatening, unresectable, locally advanced 5 , 6 or metastatic 7 , 8 tumors. There is no standard therapy for locally advanced or metastatic basal-cell carcinoma. The survival time in metastatic basal-cell carcinoma varies widely, but the median is 8 months. 7 , 9 Basal-cell carcinoma is associated with mutations in components of . . .
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa0905360Titel-ID: cdi_proquest_journals_223913959
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Anilides, Antineoplastic Agents - administration & dosage, Antineoplastic Agents - adverse effects, Antineoplastic Agents - pharmacokinetics, Benzimidazoles - administration & dosage, Benzimidazoles - adverse effects, Benzimidazoles - pharmacokinetics, Biological and medical sciences, Cancer, Carcinoma, Carcinoma, Basal Cell - drug therapy, Carcinoma, Basal Cell - genetics, Carcinoma, Basal Cell - secondary, Dermatology, Dose-Response Relationship, Drug, Drug dosages, Enzyme inhibitors, Evaluation, Female, Gene Expression, Gene mutations, General aspects, Genetic aspects, Health aspects, Hedgehog Proteins - antagonists & inhibitors, Humans, Male, Medical sciences, Middle Aged, Mutation, Patched Receptors, Patched-1 Receptor, Polymerase Chain Reaction, Pyridines, Receptors, Cell Surface - genetics, Receptors, Cell Surface - metabolism, RNA, Messenger - metabolism, Sequence Analysis, DNA, Signal Transduction - drug effects, Skin cancer, Skin Neoplasms - drug therapy, Skin Neoplasms - genetics, Skin Neoplasms - pathology, Transcription Factors - genetics, Transcription Factors - metabolism, Tumors of the skin and soft tissue. Premalignant lesions, Zinc Finger Protein GLI1